https://scholars.lib.ntu.edu.tw/handle/123456789/567643
標題: | Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study | 作者: | Bai Y.M. Chen T.T. WEI-SHIUNG YANG Chi Y.-C. Lin C.-C. Liou Y.-J. Wang Y.-C. Su T.-P. Chou P. Chen J.-Y. |
關鍵字: | Adiponectin; Antipsychotic agents; Metabolic syndrome | 公開日期: | 2009 | 卷: | 111 | 期: | 1-3 | 起(迄)頁: | 1-8 | 來源出版物: | Schizophrenia Research | 摘要: | Introduction: Adiponectin, an adipocyte-derived hormone controlling lipid and carbohydrate metabolism, has been suggested to be a biomarker for metabolic syndrome in the general population. This study investigated the association between adiponectin levels and metabolic syndrome in patients treated with atypical antipsychotics. Methods: Anthropometric and metabolic parameters and serum adiponectin levels were assessed in hospitalized patients with schizophrenia who had used the same atypical antipsychotic for at least 3?months. Retrospective reviews of the patients' medical records were conducted to obtain demographic data and pretreatment characteristics. Results: The study included 567 schizophrenia patients treated with clozapine (n = 231), olanzapine (n = 94) and risperidone (n = 242), for an average of 45.8 ± 27.8?months. The prevalence of metabolic syndrome among all subjects was 23.8%. The clozapine group had a higher prevalence of metabolic syndrome (28.7%) than did the olanzapine (24.2%) and risperidone groups (19.5%) (P = 0.039), and the clozapine group had lower levels of adiponectin (8.46 ± 6.02?mg/mL) than did the olanzapine (10.26 ± 4. 9?mg/mL) and risperidone groups (10.69 ± 7.43?mg/mL) (P = 0.001). Adiponectin level was negatively correlated with body mass index (BMI) increase after initiation of antipsychotic treatment. Cross-sectional regression analysis showed that age (OR, = 1.042, P = 0.001), BMI (OR = 1.404, P < 0.0001), and adiponectin level (OR = 0.862, P < 0.0001) were significant factors in the presence of metabolic syndrome. Significant predictors of metabolic syndrome were age at initiation of antipsychotic treatment (OR = 1.04, P = .007), BMI at initiation of antipsychotic treatment (OR = 1.44, P < 0.0001), BMI increase after initiation of antipsychotic treatment (OR = 1.40, P < 0.0001), and adiponectin level (OR = 0.86, P < 0.0001). Conclusion: Lower levels of adiponectin and weight gain after taking antipsychotics are associated with higher risk of metabolic syndrome in patients taking atypical antipsychotics. Crown Copyright ? 2009. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-67349244019&doi=10.1016%2fj.schres.2009.03.014&partnerID=40&md5=e43a091fc3f102208799ea01c4e244b1 https://scholars.lib.ntu.edu.tw/handle/123456789/567643 |
ISSN: | 0920-9964 | DOI: | 10.1016/j.schres.2009.03.014 | SDG/關鍵字: | adiponectin; clozapine; olanzapine; risperidone; adult; age distribution; anthropometry; article; body mass; controlled study; female; human; major clinical study; male; medical record review; metabolic parameters; metabolic syndrome X; patient compliance; prevalence; priority journal; schizophrenia; treatment duration; Adiponectin; Adult; Antipsychotic Agents; Body Mass Index; Cohort Studies; Cross-Sectional Studies; Female; Humans; Logistic Models; Male; Metabolic Diseases; Middle Aged; Retrospective Studies; Schizophrenia; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。